These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 9578821)

  • 21. Growth hormone binding protein and growth hormone availability in acromegalic patients treated with long-acting octreotide (Sandostatin-LAR).
    Fisker S; Kaal A; Montini M; Pedroncelli A; Pagani G; Orskov H
    Eur J Endocrinol; 1997 Jan; 136(1):61-6. PubMed ID: 9037128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly.
    Lorcy Y; Dejager S; Chanson P;
    Pituitary; 2000 Nov; 3(3):193-7. PubMed ID: 11383486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of lanreotide and octreotide LAR for treatment of acromegaly.
    Turner HE; Vadivale A; Keenan J; Wass JA
    Clin Endocrinol (Oxf); 1999 Sep; 51(3):275-80. PubMed ID: 10469005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly.
    de Herder WW; Taal HR; Uitterlinden P; Feelders RA; Janssen JA; van der Lely AJ
    Eur J Endocrinol; 2005 Jul; 153(1):67-71. PubMed ID: 15994747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.
    Mercado M; Borges F; Bouterfa H; Chang TC; Chervin A; Farrall AJ; Patocs A; Petersenn S; Podoba J; Safari M; Wardlaw J;
    Clin Endocrinol (Oxf); 2007 Jun; 66(6):859-68. PubMed ID: 17465997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR.
    Alexopoulou O; Abrams P; Verhelst J; Poppe K; Velkeniers B; Abs R; Maiter D
    Eur J Endocrinol; 2004 Sep; 151(3):317-24. PubMed ID: 15362960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Sandostatin LAR on serum leptin levels in patients with acromegaly.
    Tan KC; Tso AW; Lam KS
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):31-5. PubMed ID: 11167923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR.
    Ashwell SG; Bevan JS; Edwards OM; Harris MM; Holmes C; Middleton MA; James RA
    Eur J Endocrinol; 2004 Apr; 150(4):473-80. PubMed ID: 15080776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
    Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly.
    Biermasz NR; Pereira AM; Smit JW; Romijn JA; Roelfsema F
    Growth Horm IGF Res; 2005 Jun; 15(3):200-6. PubMed ID: 15935982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
    Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve 'safe' growth hormone levels.
    Lindsay JR; McConnell EM; Hunter SJ; McCance DR; Sheridan B; Atkinson AB
    Pituitary; 2004; 7(3):139-144. PubMed ID: 16328564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly.
    Kendall-Taylor P; Miller M; Gebbie J; Turner S; al-Maskari M
    Pituitary; 2000 Oct; 3(2):61-5. PubMed ID: 11141697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS; Musolino NR; Salgado LR; Bronstein MD
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995).
    Caron P; Cogne M; Gusthiot-Joudet B; Wakim S; Catus F; Bayard F
    Eur J Endocrinol; 1995 Mar; 132(3):320-5. PubMed ID: 7889181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and efficacy of the long-acting somatostatin analogue somatuline in acromegaly.
    Johnson MR; Chowdrey HS; Thomas F; Grint C; Lightman SL
    Eur J Endocrinol; 1994 Mar; 130(3):229-34. PubMed ID: 7908838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.
    Newman CB; Melmed S; Snyder PJ; Young WF; Boyajy LD; Levy R; Stewart WN; Klibanski A; Molitch ME; Gagel RF
    J Clin Endocrinol Metab; 1995 Sep; 80(9):2768-75. PubMed ID: 7673422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Forty month follow-up of persistent and difficultly controlled acromegalic patients treated with depot long acting somatostatin analog octreotide.
    Yetkin DO; Boysan SN; Tiryakioglu O; Yalin AS; Kadioglu P
    Endocr J; 2007 Jun; 54(3):459-64. PubMed ID: 17495423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients.
    Lancranjan I; Bruns C; Grass P; Jaquet P; Jervell J; Kendall-Taylor P; Lamberts SW; Marbach P; Orskov H; Pagani G; Sheppard M; Simionescu L
    Metabolism; 1996 Aug; 45(8 Suppl 1):67-71. PubMed ID: 8769387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
    Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.